Dominik Schnerch
Overview
Explore the profile of Dominik Schnerch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Greil C, Felthaus J, Follo M, Ihorst G, Ewerth D, Schuler J, et al.
Am J Cancer Res
. 2021 Aug;
11(7):3698-3710.
PMID: 34354869
Targeting mitosis by taxanes is one of the most common chemotherapeutic approaches in various malignant solid tumors, but cancer cells may survive antimitotic treatment with attainable concentrations due to mitotic...
2.
Ganier O, Schnerch D, Nigg E
Open Biol
. 2018 Jun;
8(6).
PMID: 29899122
Centrosome aberrations disrupt tissue architecture and may confer invasive properties to cancer cells. Here we show that structural centrosome aberrations, induced by overexpression of either Ninein-like protein (NLP) or CEP131/AZI1,...
3.
Nigg E, Schnerch D, Ganier O
Cold Spring Harb Symp Quant Biol
. 2018 Apr;
82:137-144.
PMID: 29610243
Centrosomes determine the disposition of microtubule networks and thereby contribute to regulate cell shape, polarity, and motility, as well as chromosome segregation during cell division. Additionally, centrioles, the core components...
4.
Ganier O, Schnerch D, Oertle P, Lim R, Plodinec M, Nigg E
EMBO J
. 2018 Mar;
37(9).
PMID: 29567643
Centrosomes are the main microtubule-organizing centers of animal cells. Although centrosome aberrations are common in tumors, their consequences remain subject to debate. Here, we studied the impact of structural centrosome...
5.
Schnerch D, Schuler J, Follo M, Felthaus J, Wider D, Klingner K, et al.
Oncotarget
. 2017 Apr;
8(13):21153-21166.
PMID: 28416751
Elderly and frail patients, diagnosed with acute myeloid leukemia (AML) and ineligible to undergo intensive treatment, have a dismal prognosis. The small molecule inhibitor volasertib induces a mitotic block via...
6.
Ewerth D, Schmidts A, Hein M, Schnerch D, Kvainickas A, Greil C, et al.
Oncotarget
. 2016 Jul;
7(30):48220-48230.
PMID: 27374082
The E3 ubiquitin ligase and tumor suppressor APC/CCdh1 is crucial for cell cycle progression, development and differentiation in many cell types. However, little is known about the role of Cdh1...
7.
Haug S, Schnerch D, Halbach S, Mastroianni J, Dumit V, Follo M, et al.
Int J Cancer
. 2014 Oct;
136(10):2328-40.
PMID: 25346496
Metastatic ovarian cancer has a dismal prognosis and current chemotherapeutic approaches have very limited success. Metadherin (MTDH) is expressed in human ovarian cancer tissue and its expression inversely correlates with...
8.
Schnerch D, Lausch E, Becker H, Felthaus J, Pfeifer D, Mundlos S, et al.
Leuk Lymphoma
. 2013 Oct;
55(8):1930-2.
PMID: 24138303
No abstract available.
9.
Schnerch D, Follo M, Felthaus J, Engelhardt M, Wasch R
PLoS One
. 2013 Sep;
8(9):e74379.
PMID: 24058555
Antimitotic agents are frequently used to treat solid tumors and hematologic malignancies. However, one major limitation of antimitotic approaches is mitotic slippage, which is driven by slow degradation of cyclin...
10.
Schnerch D, Schmidts A, Follo M, Udi J, Felthaus J, Pfeifer D, et al.
Haematologica
. 2013 Jul;
98(12):1886-95.
PMID: 23812934
Spindle poison-based therapy is of only limited benefit in acute myeloid leukemia while lymphoblastic leukemia/lymphoma responds well. In this study, we demonstrated that the spindle assembly checkpoint protein BubR1 was...